Your session is about to expire
← Back to Search
Durvalumab + Chemoradiation for Non-Small Cell Lung Cancer
Study Summary
This trial is testing whether adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken certain medications recently.My early-stage lung cancer returned in the lymph nodes after surgery.My side effects from previous cancer treatments have mostly improved within 45 days, except for hair loss or skin color changes.I do not have severe lung inflammation.I have not had a bone marrow or organ transplant.You cannot have had serious allergic reactions to certain types of medications in the past.You have a measurable disease according to specific guidelines within 4 weeks before signing up for the trial.If you can have a baby, you need to have a recent test that shows you are not pregnant.I have not lost more than 10% of my weight unintentionally in the last month.You cannot be pregnant or breastfeeding because the treatment may harm the baby.I am currently not on any conflicting medications or treatments.I have not had any treatment with specific antibodies or drugs.You need to have had a heart test called electrocardiography (ECG) done within 6 weeks before joining the study.I am using a birth control method that is not listed as highly effective.I have a history of heart issues or have been treated with heart-affecting drugs.I have a history of disorders related to lymphocyte proliferation.I have been diagnosed with stage IIIA/B/C non-small cell lung cancer that cannot be surgically removed.I do not have an active tuberculosis infection.You need to have a measurable tumor according to specific guidelines for evaluating tumors.My cancer returned in the lymph nodes after early-stage lung cancer surgery.I do not have any autoimmune or neuromuscular syndromes.I will not undergo any cancer treatments not approved by this study after my initial chemo/radiation.I have stage IIIA/B/C non-small cell lung cancer or it has come back in the nodes after surgery.My first chest CT scan after treatment did not show my cancer getting worse.You must use a very effective form of birth control during sex.I have not lost more than 10% of my weight unintentionally in the last month.I do not have an active hepatitis B or C infection.I weigh more than 30 kilograms.I have not had severe infections or sepsis in the last 2 weeks.I don't have lung conditions or active lung inflammation.I have another cancer, but it won't affect this trial's treatment.I am fully active or can carry out light work.I am HIV positive and meet all the study's requirements.I am 18 years old or older.I am using effective birth control methods as required.I have not had a severe infection in the last 4 weeks.I have not had radiation on the area to be treated now.I do not have any untreated or uncontrolled illnesses.I have not had a live vaccine in the last 4 weeks.I will not donate blood or sperm while receiving the study treatment.I have a history of cancer.I haven't had any cancer except for skin cancer in the last 5 years.Your blood needs to have certain levels of cells and chemicals.My lung function tests are within the required range.I have stage IIIA/B/C non-small cell lung cancer that cannot be removed by surgery.
- Group 1: Arm A (durvalumab, chemotherapy, durvalumab)
- Group 2: Arm B (chemotherapy, durvalumab)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still room for volunteers in this research project?
"The trial is currently ongoing, according to the information provided on clinicaltrials.gov. This study was originally posted on April 9th, 2020, and the most recent update was on November 8th, 2020."
Could you please summarize the evidence for Cisplatin's safety?
"Cisplatin's safety is based on both its efficacy in prior clinical trials and its multiple rounds of data supporting safety, giving it a score of 3."
Is this study taking place at many different locations across America?
"There are 100 total sites for this study, which are located in Morgantown, Las Vegas, Elk Grove Village, and many other places. It would be most convenient for you to choose a location near you to minimize travel time and requirements."
What is the primary function of Cisplatin?
"Metastatic ureter urothelial carcinoma is most commonly treated with Cisplatin. However, Cisplatin is also useful for treating other conditions, such as lymphoma, non-hodgkin, merkel cell cancer, and locally advanced non-small cell lung cancer."
Could you tell us if Cisplatin has been used in other research projects?
"First researched in 1997, cisplatin has undergone 2799 completed clinical trials. As of now, 2047 trials are actively recruiting patients with a large portion of these taking place in Morgantown, West virginia."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Alegent Health Mercy Hospital: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger